Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer
Ad hoc announcement pursuant to Art.53 LRRoche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancerSKYSCRAPER-02, the firstrandomized study oftiragolumab in extensive stage small-cell lung cancer (ES-SCLC),did not meet its co-primary endpoint of progression-free survivalES-SCLC is a hard-to-treat disease andTecentriq plus chemotherapy remains a standard of careTiragolumab continues to be evaluated in non-small cell lung cancer (NSCLC) and other cancer types through additional phase III trials as plannedBasel, 30 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the p...
Source: Roche Investor Update - March 30, 2022 Category: Pharmaceuticals Source Type: news
Vabysmo, the first bispecific antibody in ophthalmology for nAMD and DME, approved in Japan
Dear Investor,Please find attached a press release by Chugai:https://www.roche.com/220328_IR_Chugai_Vabysmo.pdfDo not hesitate to contact us for any further questions.With best regards,Roche Investor Relations Dr. Karl MahlerPhone: +41 61 68-78503e-mail:karl.mahler@roche.com Dr. Bruno EschliPhone: +41 61 68-75284e-mail:bruno.eschli@roche.com Dr. Sabine Borngr äberPhone: +41 61 68-88027e-mail:sabine.borngraeber@roche.com Dr. Birgit MasjostPhone: +41 61 68-84814e-mail:birgit.masjost@roche.comDr. Gerard TobinPhone: +41 61 68-72942e-mail:gerard.tobin@roche.com Investor Relations North America Loren KalmPhone: +1 650...
Source: Roche Investor Update - March 28, 2022 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Roche ’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more than 20 yearsApproximately 40% of people with previously untreated DLBCL are not cured with the current standard of care and face a poor prognosis [1,2]Recommendation is based on pivotal data from the phase III POLARIX studyBasel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pol...
Source: Roche Investor Update - March 25, 2022 Category: Pharmaceuticals Source Type: news
Invitation to Roche ’s First Quarter Sales 2022 Webinar
Roche will publish its Sales Results for the 1st Quarter of 2022 prior to the opening of the Swiss Stock Exchange onMonday, 25 April 2022. 07:00 CEST / 06:00 BST / 01:00 AM EDT / 10:00 PM PDT (evening before) Release will be e-mailed and posted on the Roche IR website>click here Presentation slides will be posted on the Roche IR website>click here 14:00 – 15:30 CEST / 13:00 – 14:30 BST 08:00 – 09:30 AM EDT / 05:00 - 06:30 AM PDT The webinar will start with presentations by senior management,followed by a Q&A session. Presenters: Severin Schwan, CEO Roch...
Source: Roche Investor Update - March 25, 2022 Category: Pharmaceuticals Source Type: news
Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting
First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue to demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophyLonger-term efficacy and safety forEnspryng inneuromyelitisoptica spectrum disorder reinforce previously seen resultsAdditional data across neurological disorders, including Alzheimer ’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatmentBasel, 25 March...
Source: Roche Investor Update - March 25, 2022 Category: Pharmaceuticals Source Type: news
Roche donates additional medicines and diagnostics for Ukraine
Basel, 23 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the donation of additional medicines and diagnostics to Ukraine.Beyond the already communicated 150,000 packs of an antibiotic medicine the new donation includes another 4,600 packs of specialized medicines for the treatment of influenza, rheumatoid arthritis, SMA and various cancers. We are also donating reagents and consumables for automatic testing of up to 120,000 blood donations and 31,000 units for diabetes management.This latest donation demonstrates our commitment to meeting the need for Roche medicines and diagnostics in Ukraine whenever pos...
Source: Roche Investor Update - March 23, 2022 Category: Pharmaceuticals Source Type: news
Roche provides molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern
Roche and its subsidiary,TibMolbiol, confirm that it has tests for research use that identify the SARS-CoV-2subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and DeltaThe World Health Organization (WHO) has recently reported that the BA.2subvariant is steadily increasing in prevalence, specifically in Denmark Use of these tests assess the spread of circulating variants and can help monitor the potential impact of therapeutics, vaccines and public health interventionsAll Roche SARS-Cov-2 tests correctly identify the virus including these newsubvariantsBasel, 16 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY)...
Source: Roche Investor Update - March 16, 2022 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showedEvrysdi demonstrated a marked improvement in, orstabilisation of, motor function after two years compared to an untreated external control groupLatest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated withEvrysdi for at least 12 months were able to stand and walk within timeframes typical of healthy babiesMore than 5,000 patients have been treated withEvrysdi to date, from newborns to people...
Source: Roche Investor Update - March 16, 2022 Category: Pharmaceuticals Source Type: news
Roche Annual General Meeting 2022
All proposals of the Board of Directors approvedChristoph Franz as Chairman of the Roche Board of Directors and all other Board members standing for re-election approved;Jemilah Mahmood elected as a new member of the Board of Directors35th Consecutive dividend increase to CHF 9.30 per share Basel, 15 March 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). Owing to the ongoing high infection rates, the AGM was held with only representatives of Roche Holding Ltd and those persons req uired by the Ar...
Source: Roche Investor Update - March 15, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s virtual event on key neuromuscular data presented at the 2022 Muscular Dystrophy Association (MDA) scientific and clinical conference
We are pleased to invite investors and analysts to participate in our virtual event onWednesday, 16 March 2022, highlighting Roche data presented during the 2022 Muscular Dystrophy Association - MDA -Virtual Clinical and Scientific Conference, from 13th to 16th March.16:30 – 17:30 CET / 15:30 - 16:30 GMT11:30 – 12:30 am EDT / 8:30 – 9:30 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available fordownload at15:30 CET on the day of the event.>click here AgendaWelcomeBruno Eschli, Head of Investor Relations Neuromuscular franchi...
Source: Roche Investor Update - March 9, 2022 Category: Pharmaceuticals Source Type: news
Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio
Evrysdi ® (risdiplam) data further confirm long-term efficacy and safety data in a broad range of people with spinal muscular atrophy (SMA)Latest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated with Evrysdi for at least 12 months were able to sit, stand and walk within timeframes typical of healthy babiesNew gene therapy data in boys living with Duchenne muscular dystrophy (DMD) reports encouraging results from early stage study supporting its progress into global pivotal Phase III EMBARK studyBasel, 08 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data...
Source: Roche Investor Update - March 8, 2022 Category: Pharmaceuticals Source Type: news
Roche and three leading research institutions combine expertise on new Alzheimer ’s prevention trial
Phase III trial will evaluategantenerumab in cognitively unimpaired people with the earliest biologicalsigns ofAlzheimer ' sdiseaseRoche and research institutions have jointly leveraged their scientific expertise on Alzheimer ’s disease to design the new studyBasel, 3 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a new Phase III Alzheimer ’s disease prevention trial (SKYLINE, NCT05256134) with gantenerumab, an investigational anti-amyloid antibody that is administered subcutaneously. Roche intends to enter into a collaboration agreement with Banner Alzheimer’s Institute’s Alzheimer’s Prevention ...
Source: Roche Investor Update - March 3, 2022 Category: Pharmaceuticals Source Type: news
Invitation to Roche ’s virtual event on key neuromuscular data presented at the 2022 Muscular Dystrophy Association (MDA) scientific and clinical conference
We are pleased to invite investors and analysts to participate in our virtual event onWednesday, 16 March 2022, highlighting Roche data presented during the 2022 Muscular Dystrophy Association - MDA -Virtual Clinical and Scientific Conference, from 13th to 16th March.16:30 – 17:30 CET / 15:30 - 16:30 GMT11:30 – 12:30 am EDT / 8:30 – 9:30 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available fordownload at15:30 CET on the day of the event.>click here Access to virtual event (pre-registration required)Please pre-register for o...
Source: Roche Investor Update - February 22, 2022 Category: Pharmaceuticals Source Type: news
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
WHO ’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countriesSince the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra, as recommended in global treatment guidelinesTwelfth Roche medicine or test to be prequalified Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confi...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemi c corticosteroids and require supplemental oxygen or mechanical ventilation.1 It helps procurers in low- and middle-income countries identify priority medicines to improve access to care and support better health. (Source: Roche Investor Update)
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
